The results demonstrated that luteolin exerted significant antitumor effects in the cMet-overexpressing xenograft model of gastric cancer through cMet/Akt/ERK signaling, so it may serve as a potential therapeutic option for cMet-overexpressing gastric cancer (99). This evidence concerns the gene MET and gastric cancer.